RVMD · Revolution Medicines, Inc. · Documents

Sep 1

Current report 8-K

Director or officer change, or executive pay

Aug 9

Earnings call

Q2 2022 earnings call

Aug 9

Current report 8-K

Financial results

Aug 9

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $9.12M ▲ 4.8% Net loss $61.22M Diluted EPS -$0.82

Jul 22

Current report 8-K Events of Jul 19

Other events

Jul 13

Current report 8-K Events of Jul 9

Director or officer change, or executive pay

Jun 21

Current report 8-K Events of Jun 16

Shareholder vote results

Jun 10

Current report 8-K Events of Jun 8

Director or officer change, or executive pay

May 9

Earnings call

Q1 2022 earnings call

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $7.58M ▼ 25.2% Net loss $57.65M

Apr 26

Proxy statement DEF 14A Meeting Jun 16, 2022

Proxy statement

Apr 26

Proxy statement DEFA14A

Proxy statement

Feb 28

Current report 8-K

Financial results

Feb 28

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $29.39M ▼ 31.6% Net loss $187.09M

Jan 11

Earnings call

Q4 2021 earnings call

Jan 11

Current report 8-K

Financial results, Regulation FD disclosure, Other events

Nov 10

Earnings call

Q3 2021 earnings call

Nov 10

Current report 8-K

Financial results

Nov 10

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $1.1M ▼ 91.3% Net loss $52.94M

Nov 4

Current report 8-K Events of Nov 1

Entered into a material agreement, New debt or off-balance-sheet obligation

Aug 11

Current report 8-K

Financial results

Aug 11

Quarterly report 10-Q FY2021 Q2, ended Jun 30

Quarterly report for FY2021 Q2

Revenue $8.7M ▼ 13.2% Net loss $44.3M

Jun 23

Current report 8-K Events of Jun 22

Shareholder vote results

May 10

Current report 8-K

Financial results

May 10

Quarterly report 10-Q FY2021 Q1, ended Mar 31

Quarterly report for FY2021 Q1

Revenue $10.13M ▼ 12.3% Net loss $37.18M

May 3

Proxy statement DEFA14A

Proxy statement

Apr 30

Current report 8-K

Regulation FD disclosure

Apr 28

Proxy statement DEF 14A Meeting Jun 22, 2021

Proxy statement

Apr 28

Proxy statement DEFA14A

Proxy statement

Mar 8

Current report 8-K Events of Mar 4

Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change

Mar 2

Current report 8-K

Financial results

Mar 2

Annual report 10-K FY2020, ended Dec 31

Annual report for FY2020

Revenue $42.98M ▼ 14.1% Net loss $108.16M

Mar 2

Registration statement S-3ASR

Registration statement

Feb 3

Registration statement S-1/A

Registration statement

Feb 1

Current report 8-K

Financial results

Feb 1

Registration statement S-1

Registration statement

Nov 12

Current report 8-K

Financial results

Nov 12

Quarterly report 10-Q FY2020 Q3, ended Sep 30

Quarterly report for FY2020 Q3

Revenue $12.66M ▲ 1.2% Net loss $27.22M

Aug 10

Current report 8-K

Financial results

Aug 10

Quarterly report 10-Q FY2020 Q2, ended Jun 30

Quarterly report for FY2020 Q2

Revenue $10.03M ▼ 18.4% Net loss $27.22M

Jul 6

Registration statement S-1

Registration statement

Jun 22

Current report 8-K

Regulation FD disclosure

Jun 18

Current report 8-K Events of Jun 17

Director or officer change, or executive pay

May 14

Current report 8-K

Financial results

May 14

Quarterly report 10-Q FY2020 Q1, ended Mar 31

Quarterly report for FY2020 Q1

Revenue $11.55M ▼ 12.3% Net loss $19.52M

Apr 21

Current report 8-K Events of Apr 17

Entered into a material agreement, New debt or off-balance-sheet obligation, Other events

Mar 30

Annual report 10-K Ended Dec 31

Annual report for the period ended Dec 31, 2019

Mar 20

Current report 8-K Events of Mar 18

Director or officer change, or executive pay

Feb 18

Current report 8-K

Charter or bylaw amendment, or fiscal year change, Other events